Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Category: Uncategorized

Harmaline

Plain-language summaryIntrigue 60 / 100

Harmaline is one of the three main beta-carboline alkaloids in the ayahuasca vine (Banisteriopsis caapi) and Syrian rue (Peganum harmala). Its critical pharmacological role is reversible MAO-A inhibition, which is what allows oral DMT to reach the brain in ayahuasca brews (without an MAO-A inhibitor, gut MAO destroys oral DMT before it can act centrally). Harmaline by itself produces vivid closed-eye visual imagery at high doses but is not a classical psychedelic. The reversible MAO inhibition is safer than the irreversible MAO inhibitors used as antidepressants but still creates real food and drug interaction risks. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

34/100

A reference MAO-A inhibitor and tremor-model tool with limited novelty and thin standalone clinical signal

Harmaline is one of those compounds that earns its place in a research library not because it’s novel or therapeutically exciting, but because it does a specific job that’s hard to replicate. The beta-carboline skeleton, shared with harmine and tetrahydroharmine, has been pulling double duty in ethnobotanical and neuropharmacology research for decades, and harmaline’s particular profile, reversible MAO-A inhibition with good selectivity over MAO-B (Ki around 5 µM at human MAO-A, over 100-fold selectivity), makes it a reference compound worth having around.

The MAO-A story is the center of gravity here. As one of the primary harmala alkaloids in ayahuasca preparations, harmaline’s pharmacological role is well understood: it inhibits intestinal and hepatic MAO-A, which would otherwise degrade DMT before systemic absorption. That’s genuinely important for understanding the brew’s oral bioavailability, but it also means harmaline’s most studied context is inseparable from a multi-compound mixture. Isolating its specific contributions to human pharmacology in that context is messy, and standalone human data on harmaline is thin.

What we find more interesting from a bench standpoint is the tremor model. Harmaline-induced tremor in rodents is one of the few pharmacologically validated animal models of essential tremor, and it’s been used across dozens of labs to probe the cerebello-olivary system, test tremor-suppressing drug candidates, and understand the oscillatory physiology underlying the condition. For labs working on motor control or essential tremor biology, harmaline isnt a curiosity, it’s infrastructure.

Outside the tremor work, the compound has some utility as a broader beta-carboline pharmacology probe. The class hits multiple targets at varying concentrations, including sigma receptors and some NMDA interactions at higher doses, and harmaline lets you explore that pharmacology with a reversible agent that clears reasonably fast (plasma half-life roughly 2 to 3 hours). That’s useful for experimental designs where you need to avoid prolonged MAO-A suppression and want a cleaner washout window than irreversible inhibitors allow.

What limits the score is that the mechanism landscape is mature. Reversible MAO-A inhibition as a pharmacological concept is not new ground; moclobemide covers the clinical story more cleanly, harmine covers much of the same structural territory with arguably more CNS penetration literature, and the therapeutic promise of harmaline specifically is low. The translational signal outside of ayahuasca context is weak. We think this one belongs in the library as a reference and model compound, not as a frontier research target. The score reflects that honestly.

Novelty

20

Mechanism promise

35

In-category differentiation

32

Evidence quality

45

Translational signal

25

Research bench value

62

Rationale Harmaline’s score is driven by its genuine but narrow bench utility: the harmaline-induced tremor model is a pharmacologically validated rodent model of essential tremor used across many labs, and its rMAO-A selectivity profile (Ki ~5 µM, >100-fold over MAO-B) makes it a useful reference compound. Novelty, mechanism, differentiation, and translational scores are low because the pharmacology is mature, the clinical picture outside the ayahuasca context is thin, and better alternatives exist for most of what it does.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Beta-carboline reversible MAO-A inhibitor

A beta-carboline alkaloid from Peganum harmala and Banisteriopsis caapi; a reversible MAO-A inhibitor and component of ayahuasca.

Abstract

Harmaline (4,9-dihydro-7-methoxy-1-methyl-3H-pyrido[3,4-b]indole; CAS 304-21-2; molecular formula C13H14N2O; molecular weight 214.27) is a beta-carboline alkaloid isolated from Peganum harmala (Syrian rue) and Banisteriopsis caapi (ayahuasca vine). The compound is a reversible MAO-A inhibitor (Ki approximately 5 microM at human MAO-A) with greater than 100-fold selectivity over MAO-B; this reversible MAO-A inhibition is central to the pharmacology of ayahuasca, where harmaline (and harmine) prevent intestinal breakdown of the DMT in the brew, allowing oral activity. Harmaline itself has serotonergic and tremorgenic effects in animals and mild psychoactive effects in humans. Plasma half-life is approximately 2 to 3 hours. Used as a reference reversible MAO-A inhibitor and as a research probe for beta-carboline pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-337Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Cyproheptadine

Plain-language summaryIntrigue 56 / 100

Cyproheptadine, sold as Periactin, is a first-generation antihistamine that also potently blocks 5-HT2A and 5-HT2C serotonin receptors. The combination gives it three fairly distinct clinical roles: appetite stimulation (5-HT2C blockade) used in pediatric failure-to-thrive and in cachexia; treatment of serotonin syndrome (5-HT2A blockade rapidly reverses the toxidrome); and migraine prophylaxis. The H1 and anticholinergic activity produces sedation and dry mouth as expected for a first-generation antihistamine. The serotonin syndrome reversal use is the most clinically important and is not interchangeable with other antihistamines. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

45/100

Old approved antihistamine with genuine 5-HT2 probe value and sole antidote status in serotonin syndrome

Cyproheptadine has been around since 1961. That fact alone shapes how you evaluate it as a research compound. The mechanism, the clinical uses, the pharmacology — all of it is mapped. There’s no meaningful “is this real” question left to ask.

What keeps it relevant is a narrow but genuinely useful set of properties. The dual H1 and 5-HT2A/5-HT2C antagonism profile isn’t something you replicate cleanly with newer, more selective agents. If you need to study the serotonin syndrome reversal mechanism or the appetite-stimulation pathway driven by 5-HT2C blockade, cyproheptadine is the canonical tool. It’s what investigators reach for when they want the combined H1/5-HT2 blockade signal in a single compound. That’s probe value: real, but narrow.

The serotonin syndrome angle is probably the most clinically interesting thing happening with this compound right now. It remains the only compound with a specific pharmacological rationale as an antidote, and as SSRI/SNRI prescriptions have climbed and combinations with triptans, tramadol, and other serotonergic agents become more common, there’s renewed interest in the reversal mechanism. Honest assessment: most of this is clinical pharmacology, not bench discovery. The compound isnt opening new mechanistic territory. Its confirming what we already know.

The post-SSRI sexual dysfunction research angle is newer and more interesting from a bench perspective. 5-HT2A antagonism is one of the proposed interventions for PSSD, and cyproheptadine gets cited in those discussions. But the evidence there is anecdotal-to-preliminary, and more selective 5-HT2A tools like ketanserin or volinanserin exist for investigators who want clean signal without the H1 confound.

What we think: cyproheptadine earns a place in a research library because of what it is, not what it’s becoming. Its differentiation in the serotonin syndrome space is real. Its evidence quality and translational signal are solid by virtue of six decades of clinical use. But its novelty is essentially zero, and the bench-scale questions it can answer are mostly answered. A serious investigator building a new research program in 2025 would reach for this to confirm a mechanism or use it as a comparator, not as the focus of a program.

We stock it because it’s the reference 5-HT2 antagonist antihistamine with an irreplaceable clinical niche. Thats a legitimate reason. Its just not a reason to call it exciting.

Novelty

20

Mechanism promise

38

In-category differentiation

50

Evidence quality

60

Translational signal

65

Research bench value

50

Rationale Novelty is near-floor for a 1961 approved compound with fully mapped pharmacology, but differentiation and bench value score meaningfully higher because the combined H1/5-HT2A/5-HT2C profile is genuinely unique and its role as the only pharmacological serotonin syndrome antidote is uncontested; strong translational and evidence scores reflect 60-plus years of clinical use, not discovery-stage excitement.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

First-generation antihistamine + 5-HT2 antagonist

A piperidine first-generation antihistamine with 5-HT2A and 5-HT2C antagonist activity; used for appetite stimulation, serotonin syndrome reversal, and migraine prophylaxis.

Abstract

Cyproheptadine (4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine; CAS 129-03-3; molecular formula C21H21N; molecular weight 287.40) is a piperidine first-generation antihistamine with potent 5-HT2A and 5-HT2C antagonist activity, approved by the FDA in 1961 (Periactin). The compound combines H1 antihistamine activity (Ki approximately 1 nM, comparable to diphenhydramine) with strong 5-HT2 antagonism (Ki approximately 1 nM at 5-HT2A); the combined activity drives appetite stimulation (5-HT2C antagonism, the same mechanism as the appetite gain seen with olanzapine and clozapine), serotonin syndrome reversal, and migraine prophylaxis. Plasma half-life is approximately 8 hours. Approved for allergic conditions; off-label use in failure-to-thrive (pediatric appetite stimulation), serotonin syndrome (the only specific antidote besides supportive care), and post-SSRI sexual dysfunction (5-HT2A antagonism). Used as the canonical 5-HT2 antagonist antihistamine in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-353Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Testosterone (Research)

Plain-language summaryIntrigue 75 / 100

Testosterone is the principal androgen in humans, made from cholesterol in the testes (men) and ovaries plus adrenals (women). It is the foundational compound of androgen pharmacology and the active ingredient in essentially all testosterone replacement therapy plus the backbone of most non-medical anabolic steroid stacks. It binds the androgen receptor directly and is also converted on the fly into dihydrotestosterone (more potent androgen) by 5-alpha-reductase, and into estradiol by aromatase. Sold as cypionate, enanthate, propionate, undecanoate, plus gels and patches, with each ester releasing testosterone over different timescales. Schedule III in the US. The reference androgen receptor agonist for nearly all related research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundResearch workhorse

44/100

Canonical AR reference compound; foundational but thoroughly mapped, with frontier interest squarely elsewhere

Look, testosterone occupies a genuinely strange position in any research library. It’s the foundational androgen – first isolated by David, Dingemanse, Freud, and Laqueur in 1935, structure confirmed by Butenandt and Ruzicka (Nobel, 1939), and under continuous clinical deployment ever since. At this point, the AR pharmacology is about as well-characterized as receptor biology gets. Ki of roughly 0.5 nM at AR, 5-alpha-reductase conversion to the more potent DHT, aromatase conversion to estradiol. We know this chemistry cold. Thats not a criticism; its just the reality of a compound that has been under rigorous investigation for ninety years across thousands of labs.

The mechanism doesn’t earn novelty points here. Single-receptor agonism in the most saturated steroid class in pharmacology. The interesting research questions around androgen biology, tissue selectivity, AR coactivator recruitment, non-genomic signaling pathways: those are now answered more cleanly with SARMs and selective AR modulators designed specifically to probe those dimensions. If you want to study differential anabolic-to-androgenic ratios, LGD-4033 or RAD-140 are sharper instruments. If you want AR pathway studies without aromatization confound, you need to block aromatase anyway. Testosterone does AR agonism and aromatization simultaneously, which is a physiological feature but a research design confounder.

What actually scores well here is evidence quality and translational signal, and those scores are real. FDA approval for hypogonadism across multiple ester formulations (cypionate, enanthate, propionate, undecanoate). Decades of replicated RCTs, well-characterized PK across routes of administration, solid safety profiling across hematocrit, lipid, and hormonal endpoints. If you’re building a disease model around male hypogonadism or studying androgen-mediated muscle protein synthesis in a clinical context, this is your reference compound, full stop.

Where we find genuine bench value is specifically in the reference probe role. AR binding competition assays, androgen-responsive cell line studies (LNCaP, LAPC4), steroidogenesis pathway models, castration-and-replacement designs in rodents: testosterone is the canonical standard against which everything else is calibrated. That role keeps the bench value score from collapsing. But it’s not a compound you reach for because you’re curious about what it does. You reach for it because you need to establish what something else does relative to it.

Honestly, the overall score here reflects one simple fact: testosterone is so thoroughly understood that the primary research questions it can answer are mostly already answered. The frontier in androgen biology has moved to selective modulators, non-steroidal AR ligands, the androgen receptor splice variants driving castration-resistant prostate cancer, and the complex crosstalk between androgen signaling and metabolic pathways. Testosterone stays in the library as a reference standard and clinical backbone. As an object of primary investigation in 2026, its not where serious investigators are finding new ground.

Novelty

10

Mechanism promise

20

In-category differentiation

42

Evidence quality

80

Translational signal

74

Research bench value

68

Rationale Testosterone scores high on evidence quality and translational signal (FDA-approved, multi-decade RCT base) but bottoms out on novelty and mechanism promise; it’s the prototype AR agonist in the most saturated steroid pharmacology class in existence, and the live research questions in androgen biology are now prosecuted more precisely with SARMs and selective probes. The Schedule III cap (75) does not bind because the weighted score lands well below it.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous androgen / anabolic-androgenic steroid

The principal endogenous androgen; the foundational compound of androgen pharmacology and the active component of TRT and many AAS regimens.

Abstract

Testosterone (17-beta-hydroxyandrost-4-en-3-one; CAS 58-22-0; molecular formula C19H28O2; molecular weight 288.42) is the principal endogenous androgen, biosynthesized from cholesterol via pregnenolone and progesterone in Leydig cells of the testis (males) and theca cells, ovary, and adrenal cortex (females). The compound is the prototype androgen receptor agonist and the foundation of androgen pharmacology. Pharmacologically, testosterone binds AR (Ki approximately 0.5 nM) and is converted to dihydrotestosterone (DHT) by 5-alpha-reductase (more potent AR agonist) and to estradiol by aromatase (estrogen receptor agonist). Approved as testosterone replacement therapy in male hypogonadism via various ester formulations: cypionate (weekly), enanthate (weekly), propionate (every 2 to 3 days), undecanoate (oral and depot), gels and patches (daily). Schedule III in the US under the CSA. The compound is the foundation of most anabolic-androgenic steroid (AAS) regimens used non-medically for muscle building. Plasma half-life of native testosterone is short (1 to 2 hours); ester formulations release the parent compound over days. Used as the canonical AR agonist in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-386Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Sermorelin

Plain-language summaryIntrigue 60 / 100

Sermorelin is the first 29 amino acids of growth hormone releasing hormone (the active portion). It triggers natural pulsatile growth hormone release from the pituitary. Approved historically for pediatric growth hormone deficiency before being discontinued in 2008. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

38/100

Historically important GHRH fragment now superseded by longer-acting analogs with better pharmacokinetics

Sermorelin is the granddaddy of the GHRH peptide class. The 29-amino-acid N-terminal fragment of human GHRH, it retains full GHRHR agonist activity and was FDA-approved under the trade name Geref for pediatric GH deficiency before the brand was discontinued in 2008 for commercial reasons, not safety or efficacy ones. The mechanism is about as well-defined as it gets: GHRHR activation at the anterior pituitary, triggering pulsatile GH secretion. That signal has been observed and replicated in humans across multiple clinical programs, which is about the nicest thing we can say about the evidence base here.

Here’s the thing though: sermorelin is, by almost every research metric, the weakest member of the GHRH analog family available today. Its plasma half-life runs 11 to 12 minutes subcutaneously. CJC-1295 without DAC gives you a comparable pharmacological profile with a meaningfully longer active window; CJC-1295 with the drug affinity complex stretches GH stimulation across days by binding to albumin. Tesamorelin, the full GHRH(1-44) fragment stabilized for pharmaceutical use, earned FDA approval for HIV-associated lipodystrophy and carries a cleaner modern regulatory track record. Any of these outcompete sermorelin on pharmacokinetics or clinical validation, often both. For most research programs focused on the GH axis, sermorelin isnt the default choice anymore and hasnt been for some time.

The combination data with GHRPs is the most defensible current angle. Synergistic GH release when sermorelin is co-administered with ipamorelin or GHRP-2 has been documented and is mechanistically sensible: you’re hitting both GHRHR and the ghrelin receptor simultaneously, producing a larger and more sustained GH pulse than either agent alone. Some labs and compounding setups favor sermorelin specifically because of this established synergy literature. We think that’s a reasonable use case, but the same synergy is achievable with CJC-1295 and superior pharmacokinetics to boot.

Evidence quality is genuinely the bright spot. Multiple replicated clinical trials, a real regulatory history, and decades of preclinical mechanistic work give sermorelin a credibility that compounds like Epitalon or TB-500 will never match. The translational signal for GH deficiency is unambiguous. But research-merit scoring isnt about how much we trust something works for its approved indication; it’s about whether this is a compelling target right now. On that question, sermorelin lands squarely in established-mature territory: historically important, still serviceable as a GHRHR probe for acute GH axis work, but not where the interesting mechanistic questions are being asked in 2025 and 2026. The field has produced better tools for the same job.

Novelty

22

Mechanism promise

35

In-category differentiation

22

Evidence quality

62

Translational signal

60

Research bench value

38

Rationale Sermorelin’s FDA history (Geref, pediatric GH deficiency) and replicated clinical evidence are genuine assets, but the 11-12 minute plasma half-life and wide availability of CJC-1295 variants leave it in the superseded tier of GHRH analogs; low novelty and differentiation scores drag the overall into the established-mature range.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

GHRH 1-29 analog

A 29-amino-acid synthetic fragment of GHRH (residues 1-29) used for growth hormone deficiency diagnosis and treatment.

Abstract

Sermorelin (GRF 1-29; CAS 86168-78-7; molecular weight 3357.93) is a synthetic peptide consisting of the first 29 amino acids of human growth hormone releasing hormone (GHRH). The 1-29 fragment retains essentially all the GH-stimulating activity of full-length GHRH (44 residues) and was the basis for the FDA approval (under the trade name Geref) for GH deficiency in children. The brand-name product was discontinued in 2008 for commercial reasons; sermorelin is now compounded for clinical use in some jurisdictions and sold as a research chemical. The compound is administered subcutaneously and stimulates pituitary GH release through GHRH receptor activation, distinct from the ghrelin receptor agonism of GHRPs. Combination of sermorelin with a GHRP (ipamorelin, GHRP-2) produces synergistic GH release. Pharmacokinetics: plasma half-life 11 to 12 minutes; subcutaneous bioavailability good. Doses for GH deficiency are 0.3 mcg/kg subcutaneously once daily at bedtime.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-079Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Metformin

Plain-language summaryIntrigue 85 / 100

Metformin, sold as Glucophage, is the most prescribed diabetes drug in the world. Beyond glucose control, it has emerging interest in longevity; the TAME trial is investigating whether metformin slows aging in humans. The mechanism involves AMPK activation and mTOR inhibition. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

49/100

Deeply mature diabetes workhorse with a genuinely interesting longevity research program that cant fully rescue the novelty deficit

Look, metformin is one of those compounds where the interesting question isnt whether it works for its approved indication. It obviously does. Over 150 million people take it daily, the UKPDS gave us two decades of outcome data, and hepatic gluconeogenesis suppression via AMPK has been replicated by basically every lab that looked at it. The diabetes case is closed. So why are we in a research library talking about it?

The honest answer is the TAME trial. Targeting Aging with Metformin, led by Nir Barzilai at Einstein, is the first FDA-sanctioned trial explicitly designed to test a drug against biological aging endpoints in non-diabetic adults. Thats a genuinely novel use case for a 70-year-old molecule, and it drags metformin back into serious investigator conversations even if the compound itself isnt new. The trial is also methodologically important: it will establish a framework for what aging trial endpoints look like, independent of whether metformin succeeds or fails. That has bench value beyond the compound.

The cancer-prevention signal is real but messy. Observational data from diabetic cohorts shows reduced incidence across several cancer types, and multiple groups have proposed mechanisms linking AMPK activation to mTORC1 suppression and downstream effects on tumor metabolism. But those are diabetic populations on therapeutic doses, and the confounding is significant. We dont think the cancer signal is strong enough to be a primary research driver in isolation. It’s corroborating, not conclusive.

What we dont love: the mechanism isnt elegant. Complex I inhibition producing AMPK activation is blunt-instrument pharmacology. The compound hits a lot of things, the dose-response is shallow, and oral bioavailability is only 50 to 60 percent. Newer AMPK activators like AICAR and indirect effectors via AMPK-kinase biology are more useful as probes if you actually want to interrogate the pathway. Metformin is what you use when you want the whole messy biological gestalt, not when you want mechanistic precision.

The differentiation picture is also complicated. For metabolic research, semaglutide and tirzepatide have eclipsed metformin as the interesting objects. For longevity research, rapamycin via mTOR has a more defined mechanistic story and a more established preclinical track record. Metformin sits in an awkward middle space: too well-understood to be exciting, but active enough in ongoing clinical science to stay relevant. We think its worth having in the library primarily because of TAME and the longevity framing, not because of what it does at the bench.

Novelty

22

Mechanism promise

40

In-category differentiation

45

Evidence quality

72

Translational signal

70

Research bench value

62

Rationale Metformin scores well on evidence and translational signal for its primary indication but suffers badly on novelty and differentiation given its age and ubiquity; the TAME trial and cancer-prevention literature give it ongoing research relevance, but the compound is a known-quantity AMPK activator in a field now dominated by more elegant mechanistic actors.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Biguanide / AMPK activator

A first-line type 2 diabetes biguanide derived from French lilac (Galega officinalis), increasingly investigated for longevity and cancer prevention applications.

Abstract

Metformin (Glucophage; 1,1-dimethylbiguanide; CAS 657-24-9; molecular formula C4H11N5; molecular weight 129.16) is a biguanide derived from guanidine, originally identified in the 1920s from the French lilac (Galega officinalis) and approved in Europe in 1957 and the United States in 1995 for type 2 diabetes. The compound is the most prescribed oral antihyperglycemic globally. Primary mechanism is mild inhibition of mitochondrial complex I producing AMPK activation, with downstream reduction in hepatic gluconeogenesis, improved insulin sensitivity in skeletal muscle, and reduced gut glucose absorption. Beyond diabetes management, metformin has accumulated evidence in cancer prevention (reduced incidence in diabetics), cardiovascular outcomes (UKPDS, in obese diabetics), and possible longevity effects. The TAME trial (Targeting Aging with Metformin) is investigating longevity endpoints in non-diabetic populations. Pharmacokinetics: plasma half-life 4 to 9 hours; oral bioavailability 50 to 60 percent; renally excreted unchanged. Approved doses are 500 to 2550 mg per day in divided administrations. Lactic acidosis is the principal serious adverse event but is rare with appropriate renal function monitoring.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-096Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Cordyceps (Cordyceps militaris / sinensis)

Plain-language summaryIntrigue 55 / 100

Cordyceps is a medicinal mushroom traditionally used for energy and athletic performance. The active compound cordycepin (3-deoxyadenosine) has been studied as an adenosine analog and possible antiviral. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundGeneric nutrient

28/100

OTC mushroom with modest exercise signal; the interesting moiety is cordycepin, not the extract

Yeah, there’s something genuinely interesting buried in here — cordycepin (3′-deoxyadenosine) is a real adenosine analog with documented receptor activity and a modest preclinical anticancer signal — but cordyceps as a research object is not the way to get at it. If you want to study cordycepin’s adenosine receptor pharmacology or explore the nucleoside antitumor literature, you use isolated cordycepin, not a gram of mushroom extract with variable active compound content and a basket of unstandardized polysaccharides sitting alongside it.

The human evidence is real but modest. A handful of small RCTs have documented improvements in exercise tolerance and attenuated cardiovascular response to exertion — the Yi et al. data on VO2max, some follow-on work with standardized C. militaris extract — and that is genuinely more than a lot of adaptogens can claim. The problem is effect size. These are small-N studies, the magnitude of improvement is mild, and the mechanistic pathway connecting mushroom polysaccharides to better aerobic output is not well worked out. The adenosine story is plausible but, as the abstract acknowledges, incompletely characterized.

The differentiation picture is weak. Cordyceps sits in a crowded functional mushroom category alongside lion’s mane, reishi, ashwagandha, and several others with broadly similar human evidence profiles. It doesnt dominate any of those competitors on a meaningful axis. The endurance angle is probably the strongest niche, but even there the signal is not dramatic enough to make cordyceps a first-choice tool for exercise physiology research.

We don’t think the bench value is zero. Cordycepin itself is worth attention in an immunology or nucleoside-pharmacology context — it turns up in the adenosine analog literature in genuinely interesting ways, including antiproliferative work that is mechanistically distinct from standard cytotoxics. But as a whole-organism extract the utility for precision mechanistic work is limited. Standardization is inconsistent, the ratio of cordycepin to polysaccharides to ergosterol varies by source, and youre essentially working with a poorly defined mixture when the active moiety is accessible in purer form.

The OTC reality also matters. This is a product available at any supplement retailer, regulatory status is uncontrolled, and the literature base skews toward industry-adjacent work and traditional medicine scholarship rather than rigorous mechanistic investigation. Thats not disqualifying on its own, but its context for where cordyceps research has historically been prioritized. Interesting ethnobotanical history, real but limited modern evidence, and a more compelling research target in cordycepin that is accessible without the extract noise.

Novelty

16

Mechanism promise

24

In-category differentiation

28

Evidence quality

42

Translational signal

38

Research bench value

22

Rationale Cordyceps scores below the generic-nutrient cap on raw calculation — novelty is minimal for a widely-available OTC mushroom, mechanism is incompletely characterized, and the differentiation case in the adaptogen category is weak. Cordycepin has real adenosine-pharmacology interest but investigators wanting that signal would use isolated cordycepin, not a standardization-variable whole extract.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Medicinal mushroom / cordycepin source

A parasitic fungus traditionally used in Chinese medicine for fatigue and physical performance, characterized by cordycepin (3′-deoxyadenosine) bioactivity.

Abstract

Cordyceps (Cordyceps militaris and the related Cordyceps sinensis / Ophiocordyceps sinensis) are parasitic fungi traditionally used in Chinese medicine for energy, endurance, and respiratory function. The active constituents include cordycepin (3′-deoxyadenosine), polysaccharides, and ergosterol derivatives. Cordyceps militaris is now the predominant commercial form due to the rarity and protected status of wild C. sinensis. Modest cardiovascular effects (improved exercise tolerance, attenuated blood pressure response) have been documented in randomized trials. Mechanism is incompletely characterized; cordycepin has documented adenosine receptor effects and modest anticancer activity. Doses are typically 1 to 3 grams per day of mushroom extract.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-111Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Methylphenidate

Plain-language summaryIntrigue 80 / 100

Methylphenidate, sold as Ritalin and Concerta, is the most prescribed ADHD medication. It blocks dopamine and norepinephrine transporters but also produces some monoamine release. Schedule II in the US. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundResearch workhorse

48/100

The canonical DAT reuptake inhibitor, indispensable as a reference compound but not a frontier research target

Look, methylphenidate has been in the literature since 1944. Eight decades of data, thousands of trials, a mechanistic profile that most first-year pharmacology students could sketch from memory. That doesnt make it useless as a research tool. It does mean that the score here reflects research merit, not clinical validation.

The mechanism is clean and well-defined: competitive reuptake inhibition at DAT and NET, no meaningful transporter inversion unlike amphetamine-class compounds. The (R,R)-enantiomer, dexmethylphenidate, carries the bulk of pharmacological activity. This selectivity matters for probe work; if you’re trying to parse dopamine reuptake inhibition from active release in a catecholamine circuit, MPH vs. d-amphetamine is still a reasonable pairing for that experiment. Thats essentially where the bench value lives in 2026.

Evidence quality is unambiguous. FDA approval in 1955, decades of replicated phase 3 trials across pediatric and adult populations, extensive neuroimaging data from PET and fMRI paradigms, mature biomarker work. Translational signal is about as clean as you get in CNS pharmacology. If you need a DAT inhibitor with massive safety and PK characterization behind it, methylphenidate has it. We’re not questioning whether it works.

What we are questioning is whether this compound is interesting as a primary research target right now. The answer is mostly no. The mechanism isn’t new. The indication space is saturated. The interesting questions in ADHD neuropharmacology have shifted toward circuit-level characterization, non-stimulant mechanisms (viloxazine, guanfacine, atomoxetine’s NET selectivity in developmental populations), and the intersection of executive function with sleep and reward architecture. Methylphenidate is a useful comparator in those experiments, not the headline compound.

Where it retains genuine bench value is as the reference DAT reuptake inhibitor in mechanistic catecholamine studies. The releaser-versus-reuptake-inhibitor distinction is still a live question in abuse liability modeling, reinforcement learning paradigms, and dopamine clearance kinetics in striatal microdialysis work. Having an FDA-characterized compound with published PK across enantiomers and multiple extended-release formulations is useful if you’re running those comparisons. The literature depth alone makes it a credible control arm.

Schedule II scheduling is the operational reality here. Institutional DEA registration, controlled substance inventory, and the attendant paperwork are non-trivial costs for any lab. The calculated score sits well under the 65-point Schedule II ceiling, so the cap doesn’t bind, but the compliance overhead is worth naming for any group setting up a new MPH protocol.

Honestly, if you’re considering methylphenidate as a primary research target rather than a reference compound or pharmacological control, we’d ask what question you’re trying to answer that the existing literature hasn’t already addressed. The depth of that literature is both its greatest asset and the clearest argument for deprioritizing it as a frontier investigation target.

Novelty

20

Mechanism promise

28

In-category differentiation

38

Evidence quality

82

Translational signal

85

Research bench value

60

Rationale Methylphenidate scores high on evidence quality and translational signal but is severely penalized by near-zero novelty and a mechanism fully characterized for eight decades; its 2026 research value is as a pharmacological reference arm in dopaminergic studies, not as a primary investigation target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Phenethylamine DAT/NET inhibitor

A phenethylamine-class DAT and NET inhibitor FDA-approved as Ritalin and Concerta for ADHD.

Abstract

Methylphenidate (Ritalin, Concerta; CAS 113-45-1; molecular formula C14H19NO2; molecular weight 233.31) is a phenethylamine-class psychostimulant first synthesized in 1944 and approved by the FDA in 1955. The compound is a primary clinical treatment for ADHD and is also used for narcolepsy. Mechanism is dopamine and norepinephrine transporter inhibition (DAT, NET); unlike amphetamine-class stimulants, methylphenidate does not produce significant monoamine release through transporter inversion. The (R,R)-enantiomer (dexmethylphenidate) carries most of the activity. Pharmacokinetics: plasma half-life 2 to 4 hours (immediate release); extended-release formulations span 8 to 12 hours. Schedule II in the United States.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-144Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
DHEA (Dehydroepiandrosterone)

Plain-language summaryIntrigue 60 / 100

DHEA is the most abundant circulating steroid hormone, produced by the adrenal glands. Levels decline with age. It serves as a precursor to both testosterone and estrogen. Sold as a supplement with mixed evidence for benefit in healthy adults. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

33/100

Mature endogenous steroid with mixed clinical record and limited frontier research value

Look, DHEA is one of the most studied endogenous steroids on the planet, and thats kind of the problem. The literature is enormous, the compound has been an OTC supplement in the United States since the 1990s, and after thirty-plus years of serious clinical investigation the picture is underwhelming. Mixed results across virtually every indication: cognitive function in aging adults, depression, sexual function, bone density, body composition. The adrenal insufficiency angle is the most defensible, but even there the effect sizes are modest and the patient population is narrow enough that generalizability is a real concern.

The mechanism is more layered than most people credit. DHEA isn’t only an androgen/estrogen precursor. It’s also a sigma-1 receptor ligand and a positive allosteric modulator at NMDA receptors, which places it in the neurosteroid conversation alongside compounds like allopregnanolone and pregnenolone. That angle is genuine and underappreciated. But here’s the problem: if you’re running neurosteroid biology, you have cleaner probes. Sigma-1 work has more selective ligands. NMDA modulation has better characterized tools. DHEA does several things at once, none of them with the selectivity that makes a clean research question possible. The multi-target profile reads as messy rather than elegant.

The age-related decline narrative is compelling on its face. Circulating DHEAS peaks in the mid-20s and reaches 10 to 20 percent of that level by age 70. Thats a dramatic and highly reproducible fall. But replacement studies haven’t consistently reversed the endpoints that decline is supposed to explain. The working hypothesis now in serious aging research is that physiological DHEA decline may be partly a consequence of aging rather than a primary driver, and that systemic oral replacement doesn’t recapitulate the local paracrine production that matters at the tissue level. That reframe, if correct, makes the classic intervention paradigm less compelling.

Differentiation is another weak point. For hormone restoration in the clinic, direct testosterone or estrogen replacement is better characterized and clinically superior on relevant endpoints. For neurosteroid mechanism work, more selective compounds exist. DHEA occupies an uncomfortable middle ground: too mainstream and over-investigated to feel like frontier research, not specific enough mechanistically to serve as a clean probe tool.

We think the honest framing is that DHEA was a rational priority in the 1990s and 2000s, serious investigators did that work carefully, and the signal that emerged is real but modest and largely population-specific. As a reference standard for endogenous steroid panels or as a benchmark in age-related endocrine decline studies, it still earns a place in the lab. As a primary research question in 2025, the room is very crowded and the probability of a surprising new finding is low.

Novelty

18

Mechanism promise

38

In-category differentiation

25

Evidence quality

50

Translational signal

38

Research bench value

35

Rationale DHEA has a large, serious clinical literature but three decades of investigation have produced consistently modest and population-specific effects; novelty is minimal and differentiation is weak because more selective tools exist for each of its proposed mechanisms. Scored as established-mature, analogous to piracetam on the maturity axis.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous androgen precursor

An endogenous adrenal steroid hormone with androgenic and neurosteroid activity; declines with age and supplemented for hormone restoration.

Abstract

DHEA (dehydroepiandrosterone; CAS 53-43-0; molecular formula C19H28O2; molecular weight 288.42) is an endogenous adrenal steroid hormone produced by the adrenal cortex. DHEA and its sulfate (DHEAS) are the most abundant circulating steroid hormones in young adults; both decline progressively with age, reaching 10 to 20 percent of peak by age 70. The compound is a precursor for downstream androgen and estrogen synthesis and is also a sigma-1 receptor ligand and NMDA receptor PAM with neurosteroid activity. Supplementation has been studied for adrenal insufficiency, depression in older adults, sexual dysfunction, and cognitive function with mixed results. The compound is sold as a dietary supplement in the United States but is prescription-only or banned in many other jurisdictions. Doses are typically 25 to 100 mg per day; female subjects often require lower doses to avoid virilizing effects.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-160Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Ginkgo Biloba

Plain-language summaryIntrigue 52 / 100

Ginkgo biloba is a maidenhair tree leaf extract widely used for cerebral circulation and cognitive function. The ginkgolides and bilobalides are the principal active compounds. Used historically for stroke and dementia. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundOverhyped vs evidence

26/100

Overhyped cognitive herb whose flagship dementia indication failed large RCTs; narrow PAF antagonist probe value remains

Look, ginkgo biloba is one of the most studied herbals on the planet, and that’s actually part of the problem. When you have thirty years of serious clinical work on a compound and the headline result is two large negative trials, you dont have a promising research target. You have a cautionary tale about wishful mechanism extrapolation.

The chemistry is genuinely interesting at the level of pharmacognosy. EGb 761, the standardized European extract, delivers roughly 24 percent flavonoid glycosides and 6 percent terpene lactones, with ginkgolides A, B, and C plus bilobalide carrying most of the pharmacological weight. Ginkgolide B is a real platelet-activating factor antagonist, and thats the mechanism that generated the most optimism for decades. Add modest MAO inhibition and broad antioxidant activity, and you have a plausible story for cerebrovascular and cognitive effects. On paper.

The problem is that on paper is where the dementia story largely stayed. The GEM trial (DeKosky et al., JAMA 2008) randomized over 3,000 community-dwelling older adults and found no reduction in dementia incidence versus placebo. GuidAge (Vellas et al., Lancet Neurology 2012) ran for five years in a high-risk population of older adults with spontaneous memory complaints and found the same: no effect on conversion to Alzheimer’s. Two large, multi-site, well-funded randomized trials. Both negative on primary endpoints. The evidence quality is high in the sense that the trials were methodologically competent; the translational signal is poor in the sense that the compound didn’t move what mattered.

There’s a more defensible case for peripheral arterial disease. Cochrane meta-analyses on intermittent claudication find a modest walking-distance benefit, which tracks more cleanly with the PAF antagonism story than the cognitive angle ever did. But modest improvement in claudication walking distance is not a frontier research question in 2026.

We don’t see a compelling case for featuring ginkgo prominently in an active research program. Ginkgolide B retains some use as a reference PAF antagonist if your question is specifically about platelet-activating factor biology, but cleaner, more selective PAF antagonists exist for that purpose. Everything else about ginkgo is either exhaustively characterized or definitively addressed by trials that came back empty. The compound earns its place in pharmacognosy textbooks. It doesn’t earn a high spot in a library built around compounds where the frontier is still genuinely open.

Novelty

15

Mechanism promise

20

In-category differentiation

15

Evidence quality

60

Translational signal

28

Research bench value

25

Rationale Ginkgo’s PAF antagonism and antioxidant chemistry are real but decades-old, and the GEM and GuidAge trials decisively closed the dementia prevention question; the common OTC herb cap of 35 would apply categorically but the raw calculation lands at 26, making it moot.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Maidenhair tree leaf extract

Standardized extract of Ginkgo biloba leaves used for cognitive function and peripheral circulation, characterized by flavonoid glycosides and terpene lactones.

Abstract

Ginkgo biloba is the world’s oldest living tree species, with leaves used in traditional Chinese medicine and standardized extracts (EGb 761) marketed in Europe for cognitive impairment and peripheral arterial disease. Active constituents are flavonoid glycosides (24 percent in EGb 761) and terpene lactones (ginkgolides A, B, C; bilobalide; 6 percent). Pharmacology includes platelet activating factor (PAF) antagonism (ginkgolides), MAO inhibition (modest), and antioxidant activity. The clinical evidence base in dementia is mixed (large GEM and GuidAge trials negative); peripheral arterial disease evidence is more positive. Doses are typically 120 to 240 mg of standardized extract per day.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-176Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Milnacipran

Plain-language summaryIntrigue 60 / 100

Milnacipran, sold as Savella in the US (Ixel in Europe), is an SNRI primarily used for fibromyalgia. The European indication is depression. The (1S,2R)-enantiomer (levomilnacipran, Fetzima) is sold separately as a depression-focused agent. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

42/100

Approved SNRI with balanced SERT/NET profile, largely superseded by levomilnacipran for bench research

Milnacipran is a second-generation SNRI that has been on the market in France since 1997 and hit the US in 2009 as Savella, specifically for fibromyalgia. It operates the same fundamental way as venlafaxine and duloxetine – blocking serotonin and norepinephrine reuptake – but with a meaningfully different ratio. Most SNRIs are heavily SERT-biased; milnacipran sits at roughly 1:1 SERT/NET at therapeutic doses and tips toward NET preference at lower doses. Thats the whole pharmacological story here, and it’s a real if modest differentiator from the rest of its class.

Here’s the thing: that balanced profile was genuinely interesting when milnacipran first emerged, because the hypothesis that NET-biased SNRIs might address pain states differently than serotonin-dominant ones had real scientific logic. The fibromyalgia approval is direct evidence this logic played out, at least partially – FDA reviewers saw enough signal in the phase 3 data to greenlight it. The evidence base is solid. Multiple RCTs, decent N, regulatory approval in multiple jurisdictions. These aren’t things you dismiss.

What we don’t love is where milnacipran sits in the landscape right now. Levomilnacipran (Fetzima), the active (1S,2R) enantiomer, arrived in 2013 with even greater NET selectivity and largely superseded milnacipran as the compound of interest for investigators who care about the norepinephrine angle. If youre running a mechanistic study on NET inhibition ratios, you’re probably reaching for levomilnacipran or reboxetine before milnacipran. The parent compound doesn’t have a compelling edge over its own metabolite derivative, and that’s a real problem for differentiation scoring.

The fibromyalgia indication is the most distinctive thing about milnacipran from a research standpoint, and the central pain sensitization story is genuinely interesting biology. But the compound’s role there is more about demonstrating that central sensitization can be modulated pharmacologically than about milnacipran specifically being irreplaceable. Duloxetine covers overlapping ground with a larger evidence base and broader indication set. If your program is in central sensitization or fibromyalgia pathophysiology, milnacipran is a useful historical reference point but probably not your primary tool.

We see milnacipran as a mature approved pharmaceutical with well-characterized PK, a real if narrow clinical role, and limited headroom for novel research programs. It’s not junk – the fibromyalgia signal is real and the balanced monoamine profile remains a valid study tool for comparing SERT vs NET contributions across contexts. But for most bench programs in 2025, milnacipran has been superseded either by levomilnacipran for NET questions or duloxetine for fibromyalgia translational work with a larger literature behind it. The score reflects an approved, evidence-backed compound that has largely served its primary research purpose.

Novelty

22

Mechanism promise

38

In-category differentiation

28

Evidence quality

72

Translational signal

68

Research bench value

35

Rationale Milnacipran is a mature approved SNRI with genuine clinical utility in fibromyalgia, but its balanced SERT/NET profile is no longer novel and the active enantiomer levomilnacipran has largely superseded it for mechanistic research; evidence quality is high but novelty and differentiation are low, pulling the overall into the low-40s.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Serotonin-norepinephrine reuptake inhibitor

An SNRI marketed in Europe and Japan for depression and FDA-approved for fibromyalgia, with balanced SERT/NET inhibition.

Abstract

Milnacipran (Savella, Ixel; CAS 92623-85-3; molecular formula C15H22N2O; molecular weight 246.35) is a serotonin-norepinephrine reuptake inhibitor (SNRI) marketed in Europe, Japan, and Australia for major depressive disorder and FDA-approved in 2009 (Savella) for fibromyalgia. The compound has more balanced SERT and NET inhibition than venlafaxine or duloxetine (which are SERT-biased), with NET inhibition more prominent at lower doses. Approved doses are 100 mg per day in two divided administrations.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-192Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 45 46 47 48 49 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.